

Pivotal China leads \$16.5M seed funding for Oncologie

June 8, 2018 | News

Oncologie is committed to developing impactful cancer therapies to improve long-term survival of cancer patients worldwide.



Oncologie, an innovative biopharmaceutical company, recently announced that it is launching operations in both Boston and Shanghai with \$16.5 million seed financing led by Pivotal bioVenture Partners China.

Oncologie is committed to developing impactful cancer therapies to improve long-term survival of cancer patients worldwide. Building a pipeline of First and Best-in-Class clinical stage drug candidates through licensing and partnering, Oncologie is leveraging the recent regulatory changes in China to conduct parallel clinical development in China and the US to bring the next wave of Immuno-Oncology products to the two most important markets simultaneously.

Oncologie is developing multiple global programs currently in Phase 2 and Phase 3 whose mechanisms are designed to combine with immune checkpoint inhibitors to improve survival benefits. The management team of Oncologie includes industry veterans from biotech and pharma with proven track records in developing innovative cancer drugs in both China and the US.